Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-γ1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line

International Journal of Oncology

Volumn 36, Issue 6, 2010, Pages 1513-1520

  Cianfriglia, Maurizio ^a   Mallano, Alessandra ^a   Ascione, Alessandro ^a   Dupuis, Maria Luisa ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Calicheamicin; Gentuzumab ozogamicin; Immunoconjugates; Multi drug resistance; Tumor targeting

Indexed keywords

ABC TRANSPORTER; CALICHEAMICIN GAMMA1; CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BNIP3;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL STRAIN HL 60; CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77951558478     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000638     Document Type: Article

References (32)

1. Stasi R, Evangelista ML, Buccisano F, Venditti A and Amadori S: Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 34: 49-60, 2008. (Pubitemid 351168609)
2. Di Joseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK and Damle NK: Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 12: 242-249, 2006.
3. Dijoseph JF, Dougher MM, Armellino DC, Kalyandrug L, Kunz A, Boghaert ER, Hamann PR and Damle NK: CD20-specific antibody-targeted chemotherapy of non-Hodgkin's Bcell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunol Immunother 56: 1107-1117, 2007. (Pubitemid 46675304)
4. Damle NK: Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin Biol Ther 4: 1445-1452, 2004.
5. Goemans BF, Zwaan CM, Vijverberg SJ, Loonen AH, Creutzig U, Hählen K, Reinhardt D, Gibson BE, Cloos J and Kaspers GJ: Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia. Leukemia 22: 2284-2285, 2008.
6. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR and Willman CL: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94: 1086-1099, 1999.
7. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002. (Pubitemid 37328807)
8. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR and Bernstein ID: Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98: 988-994, 2001.
9. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP and Legrand O: MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 11: 7764-7772, 2005.
10. Ho MM, Hogge DE and Ling V: MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp Hematol 36: 433-442, 2008.
11. Deeley RG and Cole SP: Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 580: 1103-1111, 2006. (Pubitemid 43185290)
12. Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, Bernstein ID and Appelbaum FR: CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 109: 4168-4170, 2007.
13. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID and Linenberger ML: Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 102: 1466-1473, 2003. (Pubitemid 36988058)
14. Legrand O, Zompi S, Perrot JY, Faussat AM, Benderra Z, Chaoui D and Marie JP: P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups. Haematologica 89: 34-41, 2004. (Pubitemid 38165853)
15. Linenberger ML: CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19: 176-182, 2005.
16. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O and Marie JP: Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 18: 1246-1251, 2004. (Pubitemid 39023135)
17. Cianfriglia M, Willingham MC, Tombesi M, Scagliotti GV, Frasca G and Chersi A: P-glycoprotein epitope mapping. I. Identification of a linear human-specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multidrugresistantcells. Int J Cancer 56: 153-160, 1994. (Pubitemid 2010627) (Pubitemid 24044809)
18. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJ, Scheper RJ and Zaman GJ: Immunochemical Detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 54: 4557-4563, 1994.
19. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, Terakawa S and Ohno R: Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactiveon P-glycoprotein-expressing sublines. Leukemia 14: 1436-1443, 2000. (Pubitemid 30601355)
20. Slapak CA, Mizunuma N and Kufe DW: Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin selected human myeloid leukemia cells. Blood 84: 3113-3121, 1994. (Pubitemid 24979764) (Pubitemid 24328105)
21. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SPC and Sehested M: Sequential coexpression of the multidrug resistance gene MRP and mdr1 and their products in VP-16 (etoposide)-selectedH69 small cell lung cancer cells. Cancer Res 55: 459-462, 1995.
22. Zhou DC, Ramond S, Viguié F, Faussat AM, Zittoun R and Marie JP: Progressive resistance to homoharringtonine in human myeloleukemia K562 cells: relationship to sequential emergence of MRP and MDR1 gene overexpression and MDR1 gene translation. Int J Cancer 65: 365-371, 1996.
23. Nicolaou KC, Dai WM, Tsay SC, Estevez VA and Wrasidlo W: Designed enediynes: a new class of DNA-cleaving molecules with potent and selective anticancer activity. Science 256: 1172-1178, 1992.
24. Nicolaou KC, Smith AL and Yue EW: Chemistry and biology of natural and designed enediynes. Proc Natl Acad Sci USA 90: 5881-5888, 1993.
25. Wu CP, Calcagno AM and Ambudkar SV: Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 1: 93-105, 2008.
26. Reed JC: Bcl-2 family proteins and hematologic malignancies: history and future prospects. Blood 111: 3322-3330, 2008.
27. Mi Z, Hong B, Mirnics ZK, Tyurina YY, Kagan VE, Liang Y and Schor NF: Bcl-2-mediated potentiation of neocarzinostatin-induced apoptosis: requirement for caspase-3, sulfhydryl groups, and cleavable Bcl-2. Cancer Chemother Pharmacol 57: 357-367, 2006.
28. Rogers D, Nylander KD, Mi Z, Hu T and Schor NF: Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy. Cancer Chemother Pharmacol 62: 699-706, 2008.
29. Kasimir-Bauer S, Ottinger H, Meusers P, Beelen DW, Brittinger G, Seeber S and Scheulen ME: In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol 26: 1111-1117, 1998.
30. Walter RB, Raden BW, Kamikura DM, Cooper JA and Bernstein ID: Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin induced cytotoxicity. Blood 105: 1295-1302, 2005.
31. Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R and Falkenburg JH: Internalization and cell cycle dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18: 316-325, 2004. (Pubitemid 38240048)
32. Van der Velden VHJ, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M and van Dongen JJ: High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 18: 983-998, 2004.